

SUBSTITUTE FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 36290-0416-00-US	SERIAL NO. 10/580,662
INFORMATION DISCLOSURE STATEMENT		APPLICANT: Patrick Gerard Johnson <i>et al.</i>	
		FILING DATE October 10, 2008	GROUP 1643

*STATE INFORMATION DISCLOSURE STATEMENT*  
DEC 09 2008  
PATENT AND TRADEMARK OFFICE

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
/M.N./	AA	6,046,048	04/04/2000	CHUNTHARAPAI, <i>et al.</i>			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA
							YES      NO
/M.N./	AB	EP 0866131 A	09/23/1998	EP			

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

/M.N./	AC	Sekine, <i>et al.</i> , "Augmentation of death ligand-induced apoptosis by aminopeptidase inhibitors in human solid tumor cell lines," <i>International Journal of Cancer</i> , Vol. 94(4):485-491 (2001)
/M.N./	AD	Hyer, <i>et al.</i> , "Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis," <i>Molecular Therapy: The Journal of the American Society of Gene Therapy</i> . United States 2000, Vol. 2(4):348-358 (Oct. 2000)
/M.N./	AE	UPSTATE BIOTECHNOLOGY, Product #05-201 data sheet and Certificate of Analysis - Anti-Fas clone CH-11 antibodies (4 pages)
/M.N./	AF	Takagi <i>et al.</i> , <i>Leuk Lymphoma</i> , Vol. 42(4):577-86 (2001), Abstract only
/M.N./	AG	Cunningham <i>et al.</i> , <i>Eur J. Cancer</i> , Vol. 38(4):478-86 (2002), Abstract only
/M.N./	AH	Papamichael, <i>Oncologist</i> , Vol. 4(6):478-87 (1999), Abstract only
/M.N./	AI	Rose <i>et al.</i> , <i>Clin Colorectal Cancer</i> , Vol. 1(4):220-9 (2002), Abstract only

EXAMINER /Meera Natarajan/ DATE CONSIDERED 03/11/2009

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
36290-0416-00-USSERIAL NO.  
10/580,662

## INFORMATION DISCLOSURE STATEMENT

APPLICANT:  
Patrick Gerard Johnson et al.FILING DATE  
October 10, 2008GROUP  
1643

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
/M.N./	AA	6,046,048	04/04/2000	CHUNTHARAPAI, et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA
							YES NO
/M.N./	AB	EP 0866131 A	09/23/1998	EP			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/M.N./	AC	Sekine, et al., "Augmentation of death ligand-induced apoptosis by aminopeptidase inhibitors in human solid tumor cell lines," <i>International Journal of Cancer</i> , Vol. 94(4):485-491 (2001)
/M.N./	AD	Hyer, et al., "Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis," <i>Molecular Therapy: The Journal of the American Society of Gene Therapy</i> . United States 2000, Vol. 2(4):348-358 (Oct. 2000)
/M.N./	AE	UPSTATE BIOTECHNOLOGY, Product #05-201 data sheet and Certificate of Analysis - Anti-Fas clone CH-11 antibodies (4 pages)
/M.N./	AF	Takagi et al., <i>Leuk Lymphoma</i> , Vol. 42(4):577-86 (2001), Abstract only
/M.N./	AG	Cunningham et al., <i>Eur J. Cancer</i> , Vol. 38(4):478-86 (2002), Abstract only
/M.N./	AH	Papamichael, <i>Oncologist</i> , Vol. 4(6):478-87 (1999), Abstract only
/M.N./	AI	Rose et al., <i>Clin Colorectal Cancer</i> , Vol. 1(4):220-9 (2002), Abstract only

EXAMINER /Meera Natarajan/

DATE CONSIDERED 03/11/2009

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.